Back

MRAs in heart failure with reduced rejection fraction (HFrEF): a cornerstone of guideline-recommended medical therapy

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Redefining mineralocorticoid receptor antagonism in cardio-kidney-metabolic syndrome: from evidence to innovation Treatment Open Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Maja Cikes

University Hospital Centre Zagreb, Zagreb (Croatia)

5 More presentations in this session

Presentation thumbnail
Welcome and introduction
Professor M. Cikes (Zagreb, HR)
Slides Video
Presentation thumbnail
Improving outcomes for the heart and kidney: the role of mineralocorticoid receptor antagonists (MRAs)
Professor B. Bozkurt (Houston, US)
Slides Video
Presentation thumbnail
Non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in heart failure with mid-range and preserved ejection fraction: establishing a new standard in heart failure care
Professor J. Butler (Dallas, US)
Slides Video
Presentation thumbnail
nsMRAs: what emerging trials tell us about the future of heart failure therapy
Professor J. McMurray (Glasgow, GB)
Slides Video
Presentation thumbnail
Panel discussion and conclusion
Video

Access the full session

Session thumbnail
Redefining mineralocorticoid receptor antagonism in cardio-kidney-metabolic syndrome: from evidence to innovation
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Overcoming limitations in using the four pillars in the treatment of HFrEF
thumbnail
Congress Presentation
Barriers to mineralocorticoid receptor antagonists dose escalation in heart failure: Findings from the OPRA-HF Run-in period
thumbnail
Congress Presentation
The key role of RAASi-based therapy in symptomatic heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources